Gold prices slip slightly after recent gains; U.S. data eyed
LONDON - EKF Diagnostics Holdings plc (AIM:EKF), a global diagnostics company, has announced the repurchase of 709,125 of its own ordinary shares at a volume-weighted average price of 21.3519 pence per share. The transaction, which took place on May 7, 2025, involved shares bought back on the London Stock Exchange (LON:LSEG)’s AIM market and will be held in treasury.
The company’s share buyback saw shares purchased at prices ranging from 21.2 pence to 21.5 pence. Post-transaction, EKF Diagnostics’ issued share capital consists of 454,930,564 ordinary shares, each with one voting right. However, 4,477,012 of these shares are now held in treasury, reducing the total number of shares with voting rights to 450,453,552.
In a related transaction, EKF acquired a total of 209,125 ordinary shares from investment manager Harwood, acting on behalf of Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC. This move ensured that the indirect beneficial interest of Mr. Christopher Mills, a Non-Executive Director of EKF, remains approximately the same and does not exceed 30% of the company’s total voting rights following the buyback. Following the sale, Mr. Mills’ aggregate indirect interest in EKF stands at 132,834,180 ordinary shares.
EKF Diagnostics operates globally, with headquarters in Penarth, near Cardiff, and manufacturing sites across the United States and Germany. The company focuses on point-of-care analyzers in hematology and diabetes, as well as life sciences services, including the manufacture of enzymes and custom products for diagnostic, food, and industrial applications.
This share buyback activity is part of the company’s strategy to manage its capital structure and shareholder value. The announcement is considered to contain inside information under EU Regulation 596/2014, which has been incorporated into UK law following the European Union (Withdrawal) Act 2018.
The financial details and implications of the buyback are based on a press release statement from EKF Diagnostics Holdings plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.